tailieunhanh - Báo cáo y học: "Acute lymphoblastic leukemia subsequent to temozolomide use in a 26-year-old man: a case report."

Tuyển tập báo cáo các nghiên cứu khoa học quốc tế ngành y học dành cho các bạn tham khảo đề tài: Acute lymphoblastic leukemia subsequent to temozolomide use in a 26-year-old man: a case report. | Shaikh and Masood Journal of Medical Case Reports 2010 4 274 http content 4 1 274 jAg JOURNALOF medical ÌỤr case REPORTS CASE REPORT Open Access Acute lymphoblastic leukemia subsequent to temozolomide use in a 26-year-old man a case report Asim Jamal Shaikh Nehal Masood Abstract Introduction We report the development of acute lymphoblastic leukemia in a patient in whom temozolomide was used for the treatment of a brain tumor. Unlike that of other alkylating agents the leukemogenic potential of temozolomide is considered to be very low and very rarely are such cases reported. Case Presentation A 26-year-old Pakistani man who was treated for glioblastoma with temozolomide in an adjuvant setting was diagnosed to have acute lymphoblastic leukemia one year after stopping temozolomide. Conclusion Temozolomide is a highly active agent used in the management of high-grade brain neoplasms. The agent is generally regarded to be safe with an acceptable safety profile. Very few cases of myelodysplasia associated with temozolomide use have been reported. We report here the first case of acute lymphoblastic leukemia which developed in a young man about one year after he finished taking temozolomide. This should provide further insight into a possible toxicity profile of this alkylating agent. This finding should be of interest to physicians in general and to medical oncologists in particular. Introduction Survival rates from aggressive relapsed refractory or high-grade brain tumors are generally poor with the median survival for some being less than one year 1 . With increased survival however the long-term toxici-ties of the available chemotherapeutic agents used in aggressive brain cancers have become more prominent 2 . Alkylating agents remain the most active agents known for the treatment of aggressive and high-grade brain neoplasms. Treatment-related myelodysplasia t-MDS and acute leukemia t-AL have remained a concern of prolonged exposure to .

TÀI LIỆU LIÊN QUAN
TÀI LIỆU MỚI ĐĂNG
crossorigin="anonymous">
Đã phát hiện trình chặn quảng cáo AdBlock
Trang web này phụ thuộc vào doanh thu từ số lần hiển thị quảng cáo để tồn tại. Vui lòng tắt trình chặn quảng cáo của bạn hoặc tạm dừng tính năng chặn quảng cáo cho trang web này.